Biovest International, Inc. , a majority-owned subsidiary of Accentia Biopharmaceuticals, Inc. , today announced that an article was published in HemOnc T

Research and Markets has announced the addition of Global Markets Direct's new report "Hodgkin Lymphoma - Pipeli

Research and Markets has announced the addition of the "Triple Analysis: Lymphoma, Apoptosis and Antibodies" r

Seattle Genetics, Inc. today announced that interim results from an investigator-sponsored phase II clinical trial of ADCETRIS in patients with cutaneous T-cell lymphoma were presented at the T-Cell Lymphoma Forum being held January 26-28, 2012 in San Francisco, CA.

Spectrum Pharmaceuticals Inc. said Monday its lymphoma drug Zevalin showed promising results in a study of patients undergoing bone marrow transplant to treat an aggressive form of the blood cancer.

ST. CHARLES – Eleven years ago, Susan Moody of Batavia was a single mother of two, running four miles a day and working in Chicago.

A new immunotherapy for companion dogs with advanced-stage non-Hodgkin lymphoma (NHL) has been shown to improve survival while maintaining quality of life, according to a study published in the journal Scientific Reports. The study resulted from a collaboration between The University of Texas MD Anderson Children's Cancer Hospital in Houston and Texas A&M University College of Veterinary ...

Biovest International, Inc. , a majority-owned subsidiary of Accentia Biopharmaceuticals, Inc. , today announced that OneMedPlace, a biotechnology-focused research and media organization engaged by Biovest, has initiated research coverage on Biovest.

WHITE PLAINS, N.Y., Jan. 26, 2012 /PRNewswire/ -- Thanks to funding from The Leukemia & Lymphoma Society (LLS), Avila Therapeutics, Inc. has been testing  AVL-292, a highly selective Bruton's tyrosine ...

CRESSKILL — She gave up her summers, lunchtimes and spare moments to conduct research in her school's science lab. Her aim: discover a more cost effective way to treat lymphoma cancer by using current breast cancer drugs for patients in Third World countries.